Proteomic biomarkers of heart failure
journal contributionposted on 2018-06-04, 13:40 authored by M. Zubair Israr, Liam HeaneyLiam Heaney, Toru Suzuki
Heart failure (HF) is associated with significant morbidity and mortality. Biomarkers are used to assist clinicians with timely diagnosis, prognosis and risk prediction of patients for personalized treatment. Using modern proteomic methods such as mass spectrometry, an increasing number of novel biomarkers have been identified that further aid clinicians in the early diagnosis and outcome prediction of HF. This review focuses on the array of common and novel protein-based biomarkers which provide diagnostic and prognostic information in HF.
- Sport, Exercise and Health Sciences
Published inHeart Failure Clinics
Pages93 - 107
CitationISRAR, M.Z., HEANEY, L.M. and SUZUKI, T., 2018. Proteomic biomarkers of heart failure. Heart Failure Clinics, 14(1), pp. 93-107.
- AM (Accepted Manuscript)
Publisher statementThis work is made available according to the conditions of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence. Full details of this licence are available at: https://creativecommons.org/licenses/by-nc-nd/4.0/
NotesThis paper was accepted for publication in the journal Heart Failure Clinics and the definitive published version is available at https://doi.org/10.1016/j.hfc.2017.08.010